

Middle East and Africa Biobanking Market Report and Forecast 2024-2032

Market Report | 2024-06-26 | 140 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$3999.00
- Five User License \$5299.00
- Corporate License \$6299.00

Report description:

Middle East and Africa Biobanking Market Report and Forecast 2024-2032

Middle East and Africa Biobanking Market Size

The global biobanking market was valued at USD 72.1 billion in 2023, with the Middle East and Africa holding a significant market share. The market is driven by the growing prevalence of chronic diseases and the rising advancements in biobanking technologies. It is expected to grow at a CAGR of 5.90% during the forecast period of 2024-2032, with the values likely to attain USD 131.1 billion by 2032.

Middle East and Africa Biobanking Market Outlook

- Biomedical research, which facilitates the development of new and effective treatments, is required to tackle the rising burden of chronic diseases in the region. The growing emphasis on biomedical research activities is expected to drive market demand.
- One of the major Middle East and Africa biobanking market trends is the rising investments in the establishment of technologically advanced biobanking facilities. In May 2022 , the Al Jalila Foundation announced an investment of USD 4.6 million to establish the first robotic biobank in the United Arab Emirates, in collaboration with other organizations to advance medical research.
- The market share is also influenced by the increasing focus on the development of personalized medicine. In September 2023 , it was reported that Abu Dhabi is set to launch a biobank for human stem cells and tissues with the aim of boosting personalized medical research.

Middle East and Africa Biobanking Market Analysis

Biobanking involves the process of collecting, processing, and storing biological samples such as blood, tissue, and DNA. It offers essential resources for medical researchers to study disease mechanisms and individual responses to treatments and thus, is crucial for the development of personalized medicine. Biobanks in the Middle East and Africa region are increasingly contributing to the diversification of genetic and health data, which has been heavily skewed towards Western populations , thereby supporting the advancement of the global biobanking market . Further, the rise in the prevalence of chronic diseases like cancer,

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

diabetes, and cardiovascular conditions which requires extensive biomedical research to develop effective treatments is expected to propel the Middle East and Africa biobanking market growth in the forecast period.

One of the major market trends is the rising investments in the establishment of advanced biobanking facilities to accelerate medical discoveries. For instance, in May 2022 , the Al Jalila Foundation (a member of the Mohammed Bin Rashid Al Maktoum Global Initiatives) announced that it would establish the first robotic biobank in the United Arab Emirates, in collaboration with the Dubai Health Authority (DHA) and the Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU) to drive medical research in the areas of genetic disorders, chronic diseases and pandemics. Scheduled to be open in 2024 , the foundation has invested USD 4.6 million in building the biobank that manages seven million human biological samples and uses an automated, robotic, artificial Intelligence-based system to secure the samples in cryogenic storage. Such substantial investments in technological improvement in biobanking practices are likely to elevate the Middle East and Africa biobanking market value. The market share is also influenced by the growing impetus for the development of personalized medicine. In September 2023 , it was reported that Abu Dhabi is set to launch a biobank for human stem cells and tissues with the aim of boosting personalized medical research. This proposed project, presented by the Department of Health - Abu Dhabi and approved by the Crown Prince of Abu Dhabi, is poised to support research that will leverage advanced technology and scientific methods to advance the treatment of over 80 diseases, including cancer and blood disorders. The increased government initiatives aimed at enhancing healthcare outcomes are anticipated to bolster market share of biobanking in coming years.

Middle East and Africa Biobanking Market Segmentation??

The report offers a detailed analysis of the market based on the following segments:

Market Breakup by Product and Service

- ?□Equipment
- ?□Consumables
- ?□Service
- ?□Software

Market Breakup by Application

- ?□Regenerative Medicine
- ?□Life Science Research
- ?□Clinical Research

Market Breakup by Sample Type

- ?□Blood Tissue
- ?□Nucleic Acids
- ?□Cell Lines

Market Breakup by End User

- ?□Academic Institutions
- ?□Pharma and Biotech Companies

Market Breakup by Country

- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others

Leading Players in the Middle East and Africa Biobanking Market

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

- PHC Holdings Corporation
- Thermo Fisher Scientific, Inc.
- Becton, Dickinson and Company
- QIAGEN N.V.
- Merck KGaA
- Avantor, Inc.
- Cryoport, Inc.
- Tecan Trading AG
- Lifecode Technologies Pte Ltd
- Azenta, Inc.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

FAQs

- What is the Middle East and Africa biobanking market forecast outlook for 2024-2032?

The Middle East and Africa biobanking market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 6.89% during the forecast period of 2024-2032 and is likely to reach a market value of USD 131.1 billion by 2032.

- What are the major factors aiding the Middle East and Africa biobanking market demand?

The rising burden of chronic diseases and the growing demand for precision medicine are fuelling the demand for the market.

- What are the major Middle East and Africa biobanking market trends?

One of the significant trends in the market is the rising investments in the establishment of technologically advanced biobanking facilities. In May 2022, the Al Jalila Foundation, in collaboration with other organizations, announced an investment of USD 4.6 million to establish the first robotic biobank in the United Arab Emirates.

- What is the market segmentation based on the product and services?

Based on the products and services, the market is segmented into equipment, consumables, services, and software.

- What is the market breakup by sample type?

By sample type, the market is divided into blood tissue, nucleic acids, and cell lines.

- What are the major end users of biobanking?

End users of the market are academic institutions, pharma, and biotech companies.

- What are the applications of biobanking?

Major applications areas include regenerative medicine, life science research, and clinical research.

- What is the market segmentation by countries?

The market segmentation by countries includes Saudi Arabia, the United Arab Emirates, Nigeria, and South Africa, among others.

- Who are the key players involved in the Middle East and Africa biobanking market?

The key players in the market are PHC Holdings Corporation, Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, QIAGEN N.V., Merck KGaA, Avantor, Inc., Cryoport, Inc., Tecan Trading AG, Lifecode Technologies Pte Ltd, and Azenta, Inc.

Meta description

The Middle East and Africa biobanking market is poised for growth, driven by the expansion of the global market, which was

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

valued at USD 72.1 billion in 2023 and is projected to grow at a CAGR of 6.89% during the forecast period of 2024-2032.

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage - Key Segmentation and Scope
 - 1.4 Research Methodology
- 2 Executive Summary
- 3 Middle East and Africa Biobanking Market Overview
 - 3.1 Middle East and Africa Biobanking Market Historical Value (2017-2023)
 - 3.2 Middle East and Africa Biobanking Market Forecast Value (2024-2032)
- 4 Middle East and Africa Biobanking Market Landscape*
 - 4.1 Middle East and Africa Biobanking: Developers Landscape
 - 4.1.1 Analysis by Year of Establishment
 - 4.1.2 Analysis by Company Size
 - 4.1.3 Analysis by Region
 - 4.2 Middle East and Africa Biobanking: Product Landscape
 - 4.2.1 Analysis by Product and Service
 - 4.2.2 Analysis by Application
- 5 Middle East and Africa Biobanking Market Dynamics
 - 5.1 Market Drivers and Constraints
 - 5.2 SWOT Analysis
 - 5.2.1 Strengths
 - 5.2.2 Weaknesses
 - 5.2.3 Opportunities
 - 5.2.4 Threats
 - 5.3 Porter's Five Forces Model
 - 5.3.1 Bargaining Power of Suppliers
 - 5.3.2 Bargaining Power of Buyers
 - 5.3.3 Threat of New Entrants
 - 5.3.4 Threat of Substitutes
 - 5.3.5 Degree of Rivalry
 - 5.4 Key Demand Indicators
 - 5.5 Key Price Indicators
 - 5.6 Industry Events, Initiatives, and Trends
 - 5.7 Value Chain Analysis
- 6 Middle East and Africa Biobanking Market Segmentation (2017-2032)
 - 6.1 Middle East and Africa Biobanking Market (2017-2032) by Product and Service
 - 6.1.1 Market Overview
 - 6.1.2 Equipment
 - 6.1.3 Consumables
 - 6.1.4 Service
 - 6.1.5 Software
 - 6.2 Middle East and Africa Biobanking Market (2017-2032) by Application
 - 6.2.1 Market Overview
 - 6.2.2 Regenerative Medicine

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.2.3 Life Science Research
- 6.2.4 Clinical Research
- 6.3 Middle East and Africa Biobanking Market (2017-2032) by Sample Type
 - 6.3.1 Market Overview
 - 6.3.2 Blood Tissue
 - 6.3.3 Nucleic Acids
 - 6.3.4 Cell Lines
- 6.4 Middle East and Africa Biobanking Market (2017-2032) by End User
 - 6.4.1 Market Overview
 - 6.4.2 Academic Institutions
 - 6.4.3 Pharma and Biotech Companies
- 6.5 Middle East and Africa Biobanking Market (2017-2032) by Country
 - 6.5.1 Market Overview
 - 6.5.2 Saudi Arabia
 - 6.5.3 United Arab Emirates
 - 6.5.4 Nigeria
 - 6.5.5 South Africa
 - 6.5.6 Others
- 7 Saudi Arabia Biobanking Market (2017-2032)
 - 7.1 Saudi Arabia Biobanking Market (2017-2032) by Product and Service
 - 7.1.1 Market Overview
 - 7.1.2 Equipment
 - 7.1.3 Consumables
 - 7.1.4 Service
 - 7.1.5 Software
 - 7.2 Saudi Arabia Biobanking Market (2017-2032) by Application
 - 7.2.1 Market Overview
 - 7.2.2 Regenerative Medicine
 - 7.2.3 Life Science Research
 - 7.2.4 Clinical Research
 - 7.3 Saudi Arabia Biobanking Market (2017-2032) by Sample Type
 - 7.3.1 Market Overview
 - 7.3.2 Blood Tissue
 - 7.3.3 Nucleic Acids
 - 7.3.4 Cell Lines
 - 7.4 Saudi Arabia Biobanking Market (2017-2032) by End User
 - 7.4.1 Market Overview
 - 7.4.2 Academic Institutions
 - 7.4.3 Pharma and Biotech Companies
- 8 United Arab Emirates Biobanking Market (2017-2032)
 - 8.1 United Arab Emirates Biobanking Market (2017-2032) by Product and Service
 - 8.1.1 Market Overview
 - 8.1.2 Equipment
 - 8.1.3 Consumables
 - 8.1.4 Service
 - 8.1.5 Software
 - 8.2 United Arab Emirates Biobanking Market (2017-2032) by Application

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.2.1 Market Overview
- 8.2.2 Regenerative Medicine
- 8.2.3 Life Science Research
- 8.2.4 Clinical Research
- 8.3 United Arab Emirates Biobanking Market (2017-2032) by Sample Type
 - 8.3.1 Market Overview
 - 8.3.2 Blood Tissue
 - 8.3.3 Nucleic Acids
 - 8.3.4 Cell Lines
- 8.4 United Arab Emirates Biobanking Market (2017-2032) by End User
 - 8.4.1 Market Overview
 - 8.4.2 Academic Institutions
 - 8.4.3 Pharma and Biotech Companies
- 9 Nigeria Biobanking Market (2017-2032)
 - 9.1 Nigeria Biobanking Market (2017-2032) by Product and Service
 - 9.1.1 Market Overview
 - 9.1.2 Equipment
 - 9.1.3 Consumables
 - 9.1.4 Service
 - 9.1.5 Software
 - 9.2 Nigeria Biobanking Market (2017-2032) by Application
 - 9.2.1 Market Overview
 - 9.2.2 Regenerative Medicine
 - 9.2.3 Life Science Research
 - 9.2.4 Clinical Research
 - 9.3 Nigeria Biobanking Market (2017-2032) by Sample Type
 - 9.3.1 Market Overview
 - 9.3.2 Blood Tissue
 - 9.3.3 Nucleic Acids
 - 9.3.4 Cell Lines
 - 9.4 Nigeria Biobanking Market (2017-2032) by End User
 - 9.4.1 Market Overview
 - 9.4.2 Academic Institutions
 - 9.4.3 Pharma and Biotech Companies
- 10 South Africa Biobanking Market (2017-2032)
 - 10.1 South Africa Biobanking Market (2017-2032) by Product and Service
 - 10.1.1 Market Overview
 - 10.1.2 Equipment
 - 10.1.3 Consumables
 - 10.1.4 Service
 - 10.1.5 Software
 - 10.2 South Africa Biobanking Market (2017-2032) by Application
 - 10.2.1 Market Overview
 - 10.2.2 Regenerative Medicine
 - 10.2.3 Life Science Research
 - 10.2.4 Clinical Research
 - 10.3 South Africa Biobanking Market (2017-2032) by Sample Type

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.3.1 Market Overview
- 10.3.2 Blood Tissue
- 10.3.3 Nucleic Acids
- 10.3.4 Cell Lines
- 10.4 South Africa Biobanking Market (2017-2032) by End User
 - 10.4.1 Market Overview
 - 10.4.2 Academic Institutions
 - 10.4.3 Pharma and Biotech Companies
- 11 Regulatory Framework
- 12 Patent Analysis
 - 12.1 Analysis by Type of Patent
 - 12.2 Analysis by Publication Year
 - 12.3 Analysis by Issuing Authority
 - 12.4 Analysis by Patent Age
 - 12.5 Analysis by CPC Analysis
 - 12.6 Analysis by Patent Valuation
 - 12.7 Analysis by Key Players
- 13 Grants Analysis
 - 13.1 Analysis by Year
 - 13.2 Analysis by Amount Awarded
 - 13.3 Analysis by Issuing Authority
 - 13.4 Analysis by Grant Application
 - 13.5 Analysis by Funding Institute
 - 13.6 Analysis by Departments
 - 13.7 Analysis by Recipient Organization
- 14 Funding and Investment Analysis
 - 14.1 Analysis by Funding Instances
 - 14.2 Analysis by Type of Funding
 - 14.3 Analysis by Funding Amount
 - 14.4 Analysis by Leading Players
 - 14.5 Analysis by Leading Investors
 - 14.6 Analysis by Geography
- 15 Partnership and Collaborations Analysis
 - 15.1 Analysis by Partnership Instances
 - 15.2 Analysis by Type of Partnership
 - 15.3 Analysis by Leading Players
 - 15.4 Analysis by Geography
- 16 Supplier Landscape
 - 16.1 Market Share by Top 5 Companies
 - 16.2 PHC Holdings Corporation
 - 16.2.1 Financial Analysis
 - 16.2.2 Product Portfolio
 - 16.2.3 Demographic Reach and Achievements
 - 16.2.4 Mergers and Acquisitions
 - 16.2.5 Certifications
 - 16.3 Thermo Fisher Scientific, Inc.
 - 16.3.1 Financial Analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 16.3.2 Product Portfolio
- 16.3.3 Demographic Reach and Achievements
- 16.3.4 Mergers and Acquisitions
- 16.3.5 Certifications
- 16.4 Becton, Dickinson and Company
 - 16.4.1 Financial Analysis
 - 16.4.2 Product Portfolio
 - 16.4.3 Demographic Reach and Achievements
 - 16.4.4 Mergers and Acquisitions
 - 16.4.5 Certifications
- 16.5 QIAGEN N.V.
 - 16.5.1 Financial Analysis
 - 16.5.2 Product Portfolio
 - 16.5.3 Demographic Reach and Achievements
 - 16.5.4 Mergers and Acquisitions
 - 16.5.5 Certifications
- 16.6 Merck KGaA
 - 16.6.1 Financial Analysis
 - 16.6.2 Product Portfolio
 - 16.6.3 Demographic Reach and Achievements
 - 16.6.4 Mergers and Acquisitions
 - 16.6.5 Certifications
- 16.7 Avantor, Inc.
 - 16.7.1 Financial Analysis
 - 16.7.2 Product Portfolio
 - 16.7.3 Demographic Reach and Achievements
 - 16.7.4 Mergers and Acquisitions
 - 16.7.5 Certifications
- 16.8 Cryoport, Inc.
 - 16.8.1 Financial Analysis
 - 16.8.2 Product Portfolio
 - 16.8.3 Demographic Reach and Achievements
 - 16.8.4 Mergers and Acquisitions
 - 16.8.5 Certifications
- 16.9 Tecan Trading AG
 - 16.9.1 Financial Analysis
 - 16.9.2 Product Portfolio
 - 16.9.3 Demographic Reach and Achievements
 - 16.9.4 Mergers and Acquisitions
 - 16.9.5 Certifications
- 16.10 Lifecode Technologies Pte Ltd
 - 16.10.1 Financial Analysis
 - 16.10.2 Product Portfolio
 - 16.10.3 Demographic
 - 16.10.4 Mergers and Acquisitions
 - 16.10.5 Certifications
- 16.11 Azenta, Inc

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 16.11.1 Financial Analysis
- 16.11.2 Product Portfolio
- 16.11.3 Demographic Reach and Achievements
- 16.11.4 Mergers and Acquisitions
- 16.11.5 Certifications
- 17 Middle East and Africa Biobanking Market - Distribution Model (Additional Insight)
 - 17.1 Overview
 - 17.2 Potential Distributors
 - 17.3 Key Parameters for Distribution Partner Assessment
- 18 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 19 Company Competitiveness Analysis (Additional Insight)
 - 19.1 Very Small Companies
 - 19.2 Small Companies
 - 19.3 Mid-Sized Companies
 - 19.4 Large Companies
 - 19.5 Very Large Companies
- 20 Payment Methods (Additional Insight)
 - 20.1 Government Funded
 - 20.2 Private Insurance
 - 20.3 Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

Middle East and Africa Biobanking Market Report and Forecast 2024-2032

Market Report | 2024-06-26 | 140 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$3999.00
	Five User License	\$5299.00
	Corporate License	\$6299.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-07"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com